Catastrophic epileptic encephalopathy of unclear etiology following a mild metabolic insult generally has a poor outcome. Here, we present 2 such unrelated individuals in whom whole-exome sequencing identified the same de novo recurrent mutation (c.1207C\>T p.Arg403Cys) in the gene encoding the guanosine triphosphatase (GTPase) Dynamin-1 like Protein (DNM1L) (reference sequence NM_012062.4).

The dynamic fission and fusion of the intracellular mitochondrial network are essential to facilitate mitophagy and thus mitochondrial quality and function.^[@R1]^ During mitochondrial division, the GTPase *DNM1L* forms multimeric collars at specific fission sites, constricting portions of the mitochondrial reticulum and generating fragments for engulfment and degradation.^[@R2]^

DNM1L has been implicated in several presentations of refractory epilepsy.^[@R3]^ Both of our patients exhibited signs of preexisting developmental delay and presented with epilepsy during, or recently following, a febrile illness or exercise. Elevated lactate levels, epilepsia partialis continua, nonspecific imaging, and evidence of lipid storage myopathy all support mitochondrial dysfunction (See [table](#T1){ref-type="table"} for presentation summary and e-case report for details, [links.lww.com/NXG/A63](http://links.lww.com/NXG/A63)). This evidence supports an etiological role for DNM1L in mitochondrial epilepsy syndrome with fever sensitivity (MEFS).

###### 

Comparison of clinical presentations and investigations
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Methods {#s1}
=======

We used IN Cell Analyzer 1000 (IN Cell 1000), a previously validated high-throughput imaging method for quantifying mitophagy and mitochondrial DNA (mtDNA) in cultured fibroblasts from patients compared with cultures derived from karyotypically normal controls. Cells were immunostained for the autophagy marker Light Chain 3 (LC3) and the mitochondrial import receptor, translocase of outer membrane 20 (TOM20) and analyzed with IN Cell1000. The readout for mitophagy was colocalization of LC3 puncta with TOM20-positive mitochondria.

Results {#s2}
=======

We showed that the mitochondria in fibroblasts from both patients are lengthened and hyperpolarized (figure e-1, A and B, [links.lww.com/NXG/A62](http://links.lww.com/NXG/A62)). Total mitophagic flux was increased, showing that mitophagy is activated (figure e-1C, i). This is consistent with the mtDNA depletion documented in fibroblasts (figure e-1C, iii) and the borderline low mtDNA content in skeletal muscle from patient 1 (table).

Discussion {#s3}
==========

In 2 patients, we identified a de novo dominant mutation in *DMN1L*, the same mutation having now been identified in 4 unrelated patients with refractory epilepsy.^[@R3]^ Presentation features and investigation findings supported an underlying mitochondrial pathology. Altered mitochondrial dynamics are now a well-established cause of disease (see supplementary information for reference, [links.lww.com/NXG/A63](http://links.lww.com/NXG/A63)), and defective mitochondrial fission may both cause synaptic dysfunction^[@R1]^ and impair responses to infection.^[@R4]^

In mice, constitutive homozygous knockouts of *Drp1* (the murine homolog of *DNM1L*) do not survive embryogenesis, while conditional ablation leads to developmental defects, both associated with abnormal mitochondrial fission.^[@R5]^ Individuals heterozygous for *DNM1L* p.Arg403Cys display a milder phenotype, both in terms of mitochondrial structural and functional abnormalities and symptom severity.

Previously described cases similarly display several years of relatively normal development followed by severe, refractory epilepsy following a mild metabolic insult, vaccinations, or low-grade fever, resulting in profound global developmental delay.^[@R3]^ As in case 1, nonspecific thalamic hyperintensities were seen on MRI scans on the 2 previously reported probands with the p.Arg403Cys mutation.^[@R3]^ Case 2 demonstrated diffuse cerebral volume atrophy. These changes are in keeping with previously reported nonspecific T2 MRI hyperintensities and cerebral or cerebellar atrophy seen in other mitochondrial disorders. It remains to be seen whether MEFS is part of the same clinical spectrum of other conditions associated with status epilepticus related to febrile illnesses, i.e., new-onset refractory status epilepticus or febrile illness--related epilepsy syndrome.^[@R6]^

DNM1L is required for division of mitochondria and peroxisomes, interacting with receptor Mff and endoplasmic reticulum (ER) components. The missense mutation shared in our cases lies in the middle domain of DNM1L,^[@R3]^ impairing oligomerization and recruitment to mitochondria^[@R3]^ consistent with our findings of elongated mitochondria in fibroblasts from both patients (figure e-1A, [links.lww.com/NXG/A62](http://links.lww.com/NXG/A62)). Furthermore, knockdown of the DNM1L ortholog Drp1 in mouse cells and its ligand Mff can each cause mtDNA depletion and mitochondrial dysfunction,^[@R7]^ consistent with the borderline low mtDNA content and COX activity in skeletal muscle we demonstrated in case 1. This is likely due to increased mitophagic flux (figure e-1C, i).

Our findings suggest that *DNM1L* is implicated as a genetic contributor to MEFS. *DNM1L* p.Arg403Cys mutation screening could therefore be useful in patients with similar presentations and in identifying impaired mitochondrial fission causing synaptic dysfunction^[@R1]^ and defective response to infection.
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